Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2015, Article ID 676719, 33 pages
http://dx.doi.org/10.1155/2015/676719
Review Article

Radiotracers Used for the Scintigraphic Detection of Infection and Inflammation

RAH Radiopharmacy, Nuclear Medicine Department, Royal Adelaide Hospital, Adelaide, SA 5000, Australia

Received 28 July 2014; Revised 16 October 2014; Accepted 20 October 2014

Academic Editor: Harry Hendrikse

Copyright © 2015 Chris Tsopelas. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. I. Webber, A. M. Zimmer, M. C. Geyer, and S. M. Spies, “Use of a single-strip chromatography system to assess the lipophilic component in technetium-99m exametazime preparations,” Journal of Nuclear Medicine Technology, vol. 20, pp. 29–32, 1992. View at Google Scholar
  2. G. Pandos, S. Penglis, and C. Tsopelas, “Validation of a column method for technetium-99m exametazime quality control,” Journal of Nuclear Medicine Technology, vol. 27, no. 4, pp. 306–308, 1999. View at Google Scholar · View at Scopus
  3. Product Information Sheet for CERETEC, GE Healthcare, 2009.
  4. British Pharmacopoeia Volume IV, The Stationery Office, London, UK, 2011.
  5. R. J. Kowalsky and J. R. Perry, Radiopharmaceuticals in Nuclear Medicine Practice, Appleton-Lange, East Norwalk, Conn, USA, 1987.
  6. J. C. Bellen, B. E. Chatterton, S. Penglis, and C. Tsopelas, “Gallium-67 complexes as radioactive markers to assess gastric and colonic transit,” Journal of Nuclear Medicine, vol. 36, no. 3, pp. 513–517, 1995. View at Google Scholar · View at Scopus
  7. Product Information Sheet for INDIUM OXINE, GE Healthcare, 2006.
  8. M. Roca, E. F. J. de Vries, F. Jamar, O. Israel, and A. Signore, “Guidelines for the labelling of leucocytes with 111In-oxine,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, pp. 835–884, 2010. View at Google Scholar
  9. M. M. Edreira, L. L. Colombo, J. H. Perez, E. O. Sajaroff, and S. G. De Castiglia, “In vivo evaluation of three different 99mTc-labelled radiopharmaceuticals for sentinel lymph node identification,” Nuclear Medicine Communications, vol. 22, no. 5, pp. 499–504, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Tsopelas, “The radiopharmaceutical chemistry of 99mTc-tin fluoride colloid-labeled-leukocytes,” The Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 49, no. 4, pp. 319–324, 2005. View at Google Scholar · View at Scopus
  11. D. H. Everett, Basic Principles of Colloid Science, The Royal Society of Chemistry, Cambridge, UK, 1999.
  12. C. Tsopelas, “Physico-chemical characterisation of 99mTc-tin fluoride colloid agent used for labelling white cells,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 49, no. 6, pp. 505–516, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. T. L. Whateley and G. Steele, “Particle size and surface charge studies of a tin colloid radiopharmaceutical for liver scintigraphy,” European Journal of Nuclear Medicine, vol. 10, no. 7-8, pp. 353–357, 1985. View at Google Scholar · View at Scopus
  14. T. E. Hilditch, A. T. Elliott, T. Murray, and T. L. Whateley, “Formation of large particles in a 99Tcm-tin colloid preparation,” Nuclear Medicine Communications, vol. 7, no. 11, pp. 845–850, 1986. View at Publisher · View at Google Scholar · View at Scopus
  15. M. R. B. Puncher and P. J. Blower, “Labelling of leucocytes with colloidal tech netium-99m-SnF2: an investigation of the labelling process by autoradiography,” European Journal of Nuclear Medicine, vol. 22, no. 2, pp. 101–107, 1995. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Smith, C. Tsopelas, P. Drew, and F. D. L. Bartholomeusz, “Distribution of 99mTc-stannous fluoride colloid (SFC) in human blood as measured by an in vitro assay employing anti-CD15-antibody-magnetic beads,” Internal Medicine Journal, vol. 35, supplement, article E26, 2005. View at Google Scholar
  17. J. G. McAfee and M. L. Thakur, “Survey of radioactive agents for in vitro labeling of phagocytic leukocytes. II. Particles,” Journal of Nuclear Medicine, vol. 17, no. 6, pp. 488–492, 1976. View at Google Scholar · View at Scopus
  18. C. Tsopelas, E. Smith, P. A. Drew, and F. D. L. Bartholomeusz, “Preparation and biological evaluation of 99mTc-stannous fluoride colloid-labelled-leucocytes in rats 99mTc-stannous fluoride-labelled-leucocytes in rats,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 46, no. 8, pp. 751–763, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. S. C. Ramsay, H. Gallagher, J. Barnes, J. Maggs, N. Cassidy, and N. Ketheesan, “99mTc-Stannous Colloid (TcSnC) labelling is complement Receptor 3 (CR3) mediated and alters neutrophil priming status,” Internal Medicine Journal (Supplement), vol. 35, article E29, 2005. View at Google Scholar
  20. H. Salman, M. Bergman, H. Bessler, S. Alexandrova, and M. Djaldetti, “Ultrastructure and phagocytic activity of rat peritoneal macrophages exposed to low temperatures in vitro,” Cryobiology, vol. 41, no. 1, pp. 66–71, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. D. G. Evans, D. J. Evans Jr., and D. Y. Graham, “Adherence and internalization of Helicobacter pylori by HEp-2 cells,” Gastroenterology, vol. 102, no. 5, pp. 1557–1567, 1992. View at Google Scholar · View at Scopus
  22. D. Offen, S. Gorodin, E. Melamed, J. Hanania, and Z. Malik, “Dopamine-melanin is actively phagocytized by PC12 cells and cerebellar granular cells: possible implications for the etiology of Parkinson's disease,” Neuroscience Letters, vol. 260, no. 2, pp. 101–104, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. B. H. Mock and D. English, “Leukocyte labeling with technetium-99m tin colloids,” Journal of Nuclear Medicine, vol. 28, no. 9, pp. 1471–1477, 1987. View at Google Scholar · View at Scopus
  24. C. Tsopelas, “A study of the distribution of dextran as a sedimenting agent during the 99mTc-HMPAO leukocytes labeling procedure,” Hellenic Journal of Nuclear Medicine, vol. 46, pp. 751–763, 2004. View at Google Scholar
  25. S. J. Skehan, J. F. White, J. W. Evans et al., “Mechanism of accumulation of 99mTc-Sulesomab in inflammation,” Journal of Nuclear Medicine, vol. 44, no. 1, pp. 11–18, 2003. View at Google Scholar · View at Scopus
  26. B. M. Gallagher, J. S. Fowler, N. I. Gutterson, R. R. MacGregor, C.-N. Wan, and A. P. Wolf, “Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose,” Journal of Nuclear Medicine, vol. 19, no. 10, pp. 1154–1161, 1978. View at Google Scholar
  27. M. Silverman, M. A. Aganon, and F. P. Chinard, “Specificity of monosaccharide transport in dog kidney,” The American Journal of Physiology, vol. 218, no. 3, pp. 743–750, 1970. View at Google Scholar · View at Scopus
  28. F. Y. Lambrecht, “Evaluation of 99mTc-labeled antibiotics for infection detection,” Annals of Nuclear Medicine, vol. 25, no. 1, pp. 1–6, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. A. J. Fischman, M. C. Pike, D. Kroon et al., “Imaging focal sites of bacterial infection in rats with indium-111-labeled chemotactic peptide analogs,” Journal of Nuclear Medicine, vol. 32, no. 3, pp. 483–491, 1991. View at Google Scholar · View at Scopus
  30. C. J. van der Laken, O. C. Boerman, W. J. G. Oyen et al., “Technetium-99m-labeled chemotactic peptides in acute infection and sterile inflammation,” Journal of Nuclear Medicine, vol. 38, no. 8, pp. 1310–1315, 1997. View at Google Scholar · View at Scopus
  31. P. Gupta, A. Kumar, S. Singla et al., “Modified technique for manual synthesis of 68Ga-citrate with high radiochemical purity,” Journal of Nuclear Medicine, vol. 38, pp. 1310–1315, 1997. View at Google Scholar
  32. C. Nanni, C. Errani, L. Boriani et al., “68Ga-citrate PET/CT for evaluating patients with infections of the bone: preliminary results,” Journal of Nuclear Medicine, vol. 51, no. 12, pp. 1932–1936, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Luckey, J. R. Pollack, R. Wayne, B. N. Ames, and J. B. Neilands, “Iron uptake in Salmonella typhimurium: utilization of exogenous siderochromes as iron carriers,” Journal of Bacteriology, vol. 111, no. 3, pp. 731–738, 1972. View at Google Scholar · View at Scopus
  34. M. Petrik, G. M. Franssen, H. Haas et al., “Preclinical evaluation of two 68Ga-siderophores as potential radiopharmaceuticals for Aspergillus fumigatus infection imaging,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 7, pp. 1175–1183, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Petrik, H. Haas, P. Laverman et al., “68Ga-triacetylfusarinine C and 68Ga-ferrioxamine e for aspergillus infection imaging: uptake specificity in various microorganisms,” Molecular Imaging and Biology, vol. 16, no. 1, pp. 102–108, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. P. V. Afonso, M. Janka-Junttila, Y. J. Lee et al., “LTB4 is a signal-relay molecule during neutrophil chemotaxis,” Developmental Cell, vol. 22, no. 5, pp. 1079–1091, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Toda, T. Yokomizo, and T. Shimizu, “Leukotriene B4 receptors,” Prostaglandins and Other Lipid Mediators, vol. 68-69, pp. 575–585, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. J. E. M. van Eerd, W. J. G. Oyen, T. D. Harris et al., “Scintigraphic imaging of infectious foci with an 111In-LTB4 antagonist is based on in vivo labeling of granulocytes,” Journal of Nuclear Medicine, vol. 46, no. 5, pp. 786–793, 2005. View at Google Scholar · View at Scopus
  39. J. E. M. van Eerd, P. Laverman, W. J. G. Oyen et al., “Imaging of experimental colitis with a radiolabeled leukotriene B4 antagonist,” Journal of Nuclear Medicine, vol. 45, no. 1, pp. 89–93, 2004. View at Google Scholar · View at Scopus
  40. J. E. M. Van Eerd, M. Broekema, T. D. Harris et al., “Imaging of infection and inflammation with an improved 99mTc-labeled LTB4 antagonist,” Journal of Nuclear Medicine, vol. 46, no. 9, pp. 1546–1551, 2005. View at Google Scholar · View at Scopus
  41. H. J. J. M. Rennen, P. Laverman, J. E. M. van Eerd, W. J. G. Oyen, F. H. M. Corstens, and O. C. Boerman, “PET imaging of infection with a HYNIC-conjugated LTB4 antagonist labeled with F-18 via hydrazone formation,” Nuclear Medicine and Biology, vol. 34, no. 6, pp. 691–695, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. K. K. Solanki, J. Bomanji, Q. Siraj, M. Small, and K. E. Britton, “Tc-99m Infecton: a new class of radiopharmaceutical for infection imaging,” Journal of Nuclear Medicine, vol. 34, p. 119P, 1993. View at Google Scholar
  43. R. H. Siaens, H. J. Rennen, O. C. Boerman, R. Dierckx, and G. Slegers, “Synthesis and comparison of 99mTc-enrofloxacin and 99mTc-ciprofloxacin,” Journal of Nuclear Medicine, vol. 45, no. 12, pp. 2088–2094, 2004. View at Google Scholar · View at Scopus
  44. K. Sonmezoglu, M. Sonmezoglu, M. Halac et al., “Usefulness of 99mTc-ciprofloxacin (infecton) scan in diagnosis of chronic orthopedic infections: Comparative study with 99mTc-HMPAO leukocyte scintigraphy,” Journal of Nuclear Medicine, vol. 42, no. 4, pp. 567–574, 2001. View at Google Scholar · View at Scopus
  45. M. A. Motaleb, “Radiochemical and biological characteristics of 99mTc-difloxacin and 99mTc-pefloxacin for detecting sites of infection,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 53, no. 3, pp. 104–109, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. S. S. Qaiser, A. U. Khan, and M. R. Khan, “Synthesis, biodistribution and evaluation of 99mTc-sitafloxacin kit: a novel infection imaging agent,” Journal of Radioanalytical and Nuclear Chemistry, vol. 284, no. 1, pp. 189–193, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. M. A. Motaleb, “Preparation, quality control and stability of 99mTc-sparafloxacin complex, a novel agent for detecting sites of infection,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 52, no. 10, pp. 415–418, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. M. A. Motaleb, “Preparation and biodistribution of 99mTc-lomefloxacin and 99mTc-ofloxacin complexes,” Journal of Radioanalytical and Nuclear Chemistry, vol. 272, no. 1, pp. 95–99, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Chattopadhyay, S. Saha Das, S. Chandra et al., “Synthesis and evaluation of 99mTc-moxifloxacin, a potential infection specific imaging agent,” Applied Radiation and Isotopes, vol. 68, no. 2, pp. 314–316, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. S. O. F. Diniz, C. F. Siqueira, D. L. Nelson, J. Martin-Comin, and V. N. Cardoso, “Technetium-99m ceftizoxime kit preparation,” Brazilian Archives of Biology and Technology, vol. 48, no. 2, pp. 89–96, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. M. A. Motaleb, “Preparation of 99mTc-cefoperazone complex, a novel agent for detecting sites of infection,” Journal of Radioanalytical and Nuclear Chemistry, vol. 272, no. 1, pp. 167–171, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. F. Yurt Lambrecht, O. Yilmaz, P. Unak, B. Seyitoglu, K. Durkan, and H. Baskan, “Evaluation of  99mTc-Cefuroxime axetil for imaging of inflammation,” Journal of Radioanalytical and Nuclear Chemistry, vol. 277, no. 2, pp. 491–494, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Fazlil, M. Salouti, G. Ahmadi, F. Mirshojaei, M. Mazidi, and Z. Heydari, “Radiolabeling of ceftriaxone with 99mTc as a targeting radiopharmaceutical for Staphylococcus aureus detection in mouse model,” The Iranian Journal of Medical Physics, vol. 9, pp. 103–110, 2012. View at Google Scholar · View at Scopus
  54. S. Penglis, C. Tsopelas, and F. D. L. Bartholomeusz, “99mTc-phosphomycin as a potential infection imaging agent,” Hellenic Journal of Nuclear Medicine, vol. 4, pp. 161–164, 2001. View at Google Scholar
  55. C. Tsopelas, S. Penglis, A. Ruszkiewicz, and F. D. L. Bartholomeusz, “99mTc-Alafosfalin: an antibiotic peptide infection imaging agent,” Nuclear Medicine and Biology, vol. 30, no. 2, pp. 169–175, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. C. Tsopelas, S. Penglis, and F. D. L. Bartholomeusz, “Comparison of 99mTc-alafosfalin and 67Ga-citrate in a mouse model of bacterial infection,” Nuclear Medicine Review, vol. 5, no. 2, pp. 93–97, 2002. View at Google Scholar · View at Scopus
  57. C. Tsopelas, S. Penglis, A. Ruszkiewcz, and F. D. L. Bartholomeusz, “Inflammation imaging with 99mTc-alafosfalin in a rat model of colitis,” Hellenic Journal of Nuclear Medicine, vol. 6, pp. 33–37, 2003. View at Google Scholar
  58. S. Roohi, A. Mushtaq, and S. A. Malik, “Synthesis and biodistribution of 99mTc-vancomycin in a model of bacterial infection,” Radiochimica Acta, vol. 93, no. 7, pp. 415–418, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Roohi, A. Mushtaq, M. Jehangir, and S. A. Malik, “Synthesis, quality control and biodistribution of 99mTc-Kanamycin,” Journal of Radioanalytical and Nuclear Chemistry, vol. 267, no. 3, pp. 561–566, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Q. Shah, M. R. Khan, and A. U. Khan, “99mTc-novobiocin: a novel radiotracer for infection imaging,” Radiochimica Acta, vol. 99, no. 1, pp. 53–58, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Lupetti, M. M. Welling, U. Mazzi, P. H. Nibbering, and E. K. Pauwels, “Technetium-99m labelled fluconazole and antimicrobial peptides for imaging of Candida albicans and Aspergillus fumigatus infections,” European Journal of Nuclear Medicine, vol. 29, no. 5, pp. 674–679, 2002. View at Publisher · View at Google Scholar · View at Scopus
  62. L. A. Forstrom, B. P. Mullan, J. C. Hung, V. J. Lowe, and L. M. Thorson, “18F-FDG labelling of human leukocytes,” Nuclear Medicine Communications, vol. 21, no. 7, pp. 691–694, 2000. View at Google Scholar · View at Scopus
  63. D. Pellegrino, A. A. Bonab, S. C. Dragotakes, J. T. Pitman, G. Mariani, and E. A. Carter, “Inflammation and infection: imaging properties of 18F-FDG-labeled white blood cells versus 18F-FDG,” Journal of Nuclear Medicine, vol. 46, no. 9, pp. 1522–1530, 2005. View at Google Scholar · View at Scopus
  64. J. N. Rini and C. J. Palestro, “Imaging of infection and inflammation with 18F-FDG-labeled leukocytes,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 50, no. 2, pp. 143–146, 2006. View at Google Scholar · View at Scopus
  65. A. Signore, V. E. Soroa, and E. F. J. de Vries, “Radiolabelled white blood cells or FDG for imaging of inflammation and infection?” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 53, no. 1, pp. 23–25, 2009. View at Google Scholar · View at Scopus
  66. C. Tsopelas, G. Chew, J. Chew, T. Coates, and G. R. Russ, “The distribution of allogeneic 111In-dendritic cells in sheep,” ANZ Nuclear Medicine, vol. 37, no. 2, pp. 7–11, 2006. View at Google Scholar · View at Scopus
  67. J. Martin-Comin, M. Roca, J. M. Griñó, C. Paradell, and A. Caralps, “Clinical usefulness of 111In-oxine-labeled autologous lymphocytes in kidney-graft rejection,” European Journal of Nuclear Medicine, vol. 10, no. 7-8, pp. 308–312, 1985. View at Publisher · View at Google Scholar · View at Scopus
  68. R. A. M. J. Claessens, E. B. Koenders, O. C. Boerman et al., “Dissociation of indium from indium-111-labelled diethylene triamine penta-acetic acid conjugated non-specific polyclonal human immunoglobulin G in inflammatory foci,” European Journal of Nuclear Medicine, vol. 22, no. 3, pp. 212–219, 1995. View at Publisher · View at Google Scholar · View at Scopus
  69. M. L. Thakur, J. DeFulvio, C. H. Park et al., “Technetium-99m-labeled proteins for imaging inflammatory foci,” International Journal of Radiation Applications and Instrumentation., vol. 18, no. 6, pp. 605–612, 1991. View at Google Scholar · View at Scopus
  70. C. Tsopelas, S. Penglis, D. Miller, M. Rischmueller, and F. D. L. Bartholomeusz, “Evaluation of 99mTc-immunoglobulins for imaging infection in the rat,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 49, no. 10, pp. 915–928, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. J. W. Arndt, A. van der Sluys Veer, D. Blok et al., “A prospective comparison of 99mTc-labeled polyclonal human immunoglobulin and 111In granulocytes for localization of inflammatory bowel disease,” Acta Radiologica, vol. 33, no. 2, pp. 140–144, 1992. View at Publisher · View at Google Scholar · View at Scopus
  72. U. Karczmarczyk, A. Markiewicz, R. Mikołajczak et al., “99mTc human IgG radiolabelled by HYNIC. Biodistribution and scintigraphy of experimentally induced inflammatory lesions in animal model,” Nuclear Medicine Review, vol. 7, no. 2, pp. 107–112, 2004. View at Google Scholar · View at Scopus
  73. E. T. M. Dams, M. J. Becker, W. J. G. Oyen et al., “Scintigraphic imaging of bacterial and fungal infection in granulocytopenic rats,” Journal of Nuclear Medicine, vol. 40, no. 12, pp. 2066–2072, 1999. View at Google Scholar · View at Scopus
  74. E. T. M. Dams, W. J. G. Oyen, O. C. Boerman et al., “Technetium-99m labeled to human immunoglobulin G through the nicotinyl hydrazine derivative: a clinical study,” Journal of Nuclear Medicine, vol. 39, no. 1, pp. 119–124, 1998. View at Google Scholar · View at Scopus
  75. C. Tsopelas, S. Penglis, A. Ruskiewicz, and F. D. L. Bartholomeusz, “Scintigraphic imaging of experimental colitis with technetium-99m-infliximab in the rat,” Hellenic Journal of Nuclear Medicine, vol. 9, no. 2, pp. 85–89, 2006. View at Google Scholar · View at Scopus
  76. C. D'Alessandria, G. Malviya, A. Viscido et al., “Use of a 99mTc labeled anti-TNFα monoclonal antibody in Crohn's disease: in vitro and in vivo studies,” The Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 51, no. 4, pp. 334–342, 2007. View at Google Scholar · View at Scopus
  77. F. Conti, G. Malviya, F. Ceccarelli et al., “Role of scintigraphy with 99mTc-infliximab in predicting the response of intraarticular infliximab treatment in patients with refractory monoarthritis,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 8, pp. 1339–1347, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. http://www.snm.org/index.cfm?PageID=4655.
  79. N. Shanthly, M. R. Aruva, K. Zhang, B. Mathew, and M. L. Thakur, “99mTc-fanolesomab: affinity, pharmacokinetics and preliminary evaluation,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 50, no. 2, pp. 104–112, 2006. View at Google Scholar · View at Scopus
  80. S. L. Kipper, E. B. Rypins, D. G. Evans, M. L. Thakur, T. D. Smith, and B. Rhodes, “Neutrophil-specific 99mTc-labeled anti-CD 15 monoclonal antibody imaging for diagnosis of equivocal appendicitis,” Journal of Nuclear Medicine, vol. 41, no. 3, pp. 449–455, 2000. View at Google Scholar · View at Scopus
  81. http://www.fda.gov/medwatch/safety/2005/safety05.htm#NeutroSpec.
  82. G. Suntharalingam, M. R. Perry, S. Ward et al., “Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412,” The New England Journal of Medicine, vol. 355, no. 10, pp. 1018–1028, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. J. M. Drazen, “Volunteers at risk,” The New England Journal of Medicine, vol. 355, no. 10, pp. 1060–1061, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. K. R. Zinn, T. R. Chaudhuri, C. A. Smyth et al., “Specific targeting of activated endothelium in rat adjuvant arthritis with a 99mTc-radiolabeled E-selectin-binding peptide,” Arthritis & Rheumatism, vol. 42, pp. 641–649, 1999. View at Google Scholar
  85. S. Gratz, M. Béhé, O. C. Boerman et al., “99mTc-E-selectin binding peptide for imaging acute osteomyelitis in a novel rat model,” Nuclear Medicine Communications, vol. 22, no. 9, pp. 1003–1013, 2001. View at Publisher · View at Google Scholar · View at Scopus
  86. E. Nößner, J. E. Goldberg, C. Naftzger, S.-C. Lyu, C. Clayberger, and A. M. Krensky, “HLA-derived peptides which inhibit T cell function bind to members of the heat-shock protein 70 family,” Journal of Experimental Medicine, vol. 183, no. 2, pp. 339–348, 1996. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Broisat, L. M. Riou, V. Ardisson et al., “Molecular imaging of vascular cell adhesion molecule-1 expression in experimental atherosclerotic plaques with radiolabelled B2702-p,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 6, pp. 830–840, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. M. Nahrendorf, E. Keliher, P. Panizzi et al., “18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis,” JACC Cardiovascular Imaging, vol. 2, no. 10, pp. 1213–1222, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. A. Hatori, J. Yui, T. Yamasaki et al., “PET imaging of lung inflammation with [18F]FEDAC, a radioligand for translocator protein (18 kDa),” PLoS ONE, vol. 7, no. 9, Article ID e45065, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. O. Gaemperli, J. Shalhoub, D. R. J. Owen et al., “Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography,” European Heart Journal, vol. 33, no. 15, pp. 1902–1910, 2012. View at Publisher · View at Google Scholar · View at Scopus
  91. F. Chauveau, H. Boutin, N. van Camp, F. Dollé, and B. Tavitian, “Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 12, pp. 2304–2319, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. Y. Y. Gent, A. E. Voskuyl, R. W. Kloet et al., “Macrophage positron emission tomography imaging as a biomarker for preclinical rheumatoid arthritis: findings of a prospective pilot study,” Arthritis and Rheumatism, vol. 64, no. 1, pp. 62–66, 2012. View at Publisher · View at Google Scholar · View at Scopus
  93. C. J. van der Laken, E. H. Elzinga, M. A. Kropholler et al., “Noninvasive imaging of macrophages in rheumatoid synovitis using 11C-(R)-PK11195 and positron emission tomography,” Arthritis & Rheumatism, vol. 58, no. 11, pp. 3350–3355, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. G. Pottier, N. Bernards, F. Dollé, and R. Boisgard, “[18F]DPA-714 as a biomarker for positron emission tomography imaging of rheumatoid arthritis in an animal model,” Arthritis Research & Therapy, vol. 16, no. 2, article no. R69, 2014. View at Publisher · View at Google Scholar · View at Scopus
  95. N. Bernards, G. Pottier, B. Thézé, F. Dollé, and R. Boisgard, “In vivo evaluation of inflammatory bowel disease with the aid of μPET and the translocator protein 18 kDa radioligand [18F]DPA-714,” Molecular Imaging and Biology, 2014. View at Publisher · View at Google Scholar
  96. M. L. Immordino, F. Dosio, and L. Cattel, “Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential,” International Journal of Nanomedicine, vol. 1, no. 3, pp. 297–315, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. V. P. Torchilin, “Recent advances with liposomes as pharmaceutical carriers,” Nature Reviews Drug Discovery, vol. 4, no. 2, pp. 145–160, 2005. View at Publisher · View at Google Scholar · View at Scopus
  98. E. T. M. Dams, M. M. P. J. Reijnen, W. J. G. Oyen et al., “Imaging experimental intraabdominal abscesses with 99mTc-PEG liposomes and 99mTc-HYNIC IgG,” Annals of Surgery, vol. 229, no. 4, pp. 551–557, 1999. View at Publisher · View at Google Scholar · View at Scopus
  99. P. Laverman, E. T. M. Dams, W. J. G. Oyen et al., “A novel method to label liposomes with 99mTc by the hydrazino nicotinyl derivative,” Journal of Nuclear Medicine, vol. 40, no. 1, pp. 192–197, 1999. View at Google Scholar · View at Scopus
  100. A. H. Brouwers, D. J. De Jong, E. T. M. Dams et al., “Tc-99m-PEG-liposomes for the evaluation of colitis in Crohn's disease,” Journal of Drug Targeting, vol. 8, no. 4, pp. 225–233, 2000. View at Publisher · View at Google Scholar · View at Scopus
  101. “Product Information Sheet for ABELCET 5 mg/mL Concentrate for Suspension for Infusion,” Cephalon 2012.
  102. Product Information Sheet for AmBisome (amphotericin B) Liposome for Injection, Gilead Sciences Inc., 2012.
  103. EMA/CHMP/806058/2009/Rev. 02, Reflection Paper on the Data Requirements for Intravenous Liposomal Products Developed with Reference to an Innovator Liposomal Product, European Medicines Agency, 2013.
  104. FDA, Guidance for Industry, Liposome Drug Products, Chemistry, Manufacturing & Controls, Human Pharmacokinetics & Bioavailability, Labelling Documentation, Food and Drug Administration, 2002.
  105. J.-H. Lee, K. T. Cheng, V. Malinin et al., “99mTc-labeled therapeutic inhaled amikacin loaded liposomes,” Journal of Liposome Research, vol. 23, no. 4, pp. 336–342, 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. C. Underwood, A. W. van Eps, M. W. Ross et al., “Intravenous technetium-99m labelled PEG-liposomes in horses: a safety and biodistribution study,” Equine Veterinary Journal, vol. 44, no. 2, pp. 196–202, 2012. View at Publisher · View at Google Scholar · View at Scopus
  107. F. L. van de Veerdonk and M. G. Netea, “New insights in the immunobiology of IL-1 family members,” Frontiers in Immunology, vol. 4, article 167, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. C. J. van der Laken, O. C. Boerman, W. J. G. Oyen et al., “Specific targeting of infectious foci with radioiodinated human recombinant interleukin-1 in an experimental model,” European Journal of Nuclear Medicine, vol. 22, no. 11, pp. 1249–1255, 1995. View at Publisher · View at Google Scholar · View at Scopus
  109. C. A. Dinarello, A. Simon, and J. W. M. Van Der Meer, “Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases,” Nature Reviews Drug Discovery, vol. 11, no. 8, pp. 633–652, 2012. View at Publisher · View at Google Scholar · View at Scopus
  110. C. J. van der Laken, O. C. Boerman, W. J. G. Oyen, M. T. P. van de Ven, J. W. M. van der Meer, and F. H. M. Corstens, “Imaging of infection in rabbits with radioiodinated interleukin-1 (α and β), its receptor antagonist and a chemotactic peptide: a comparative study,” European Journal of Nuclear Medicine, vol. 25, no. 4, pp. 347–352, 1998. View at Publisher · View at Google Scholar · View at Scopus
  111. P. Barrera, C. J. Van Der Laken, O. C. Boerman et al., “Radiolabelled interleukin-1 receptor antagonist for detection of synovitis in patients with rheumatoid arthritis,” Rheumatology, vol. 39, no. 8, pp. 870–874, 2000. View at Publisher · View at Google Scholar · View at Scopus
  112. C. Prenant, C. Cawthorne, M. Fairclough, N. Rothwell, and H. Boutin, “Radiolabeling with fluorine-18 of a protein, interleukin-1 receptor antagonist,” Applied Radiation and Isotopes, vol. 68, no. 9, pp. 1721–1727, 2010. View at Publisher · View at Google Scholar · View at Scopus
  113. C. Cawthorne, C. Prenant, A. Smigova et al., “Biodistribution, pharmacokinetics and metabolism of interleukin-1 receptor antagonist (IL-1RA) using [18F]-IL1RA and PET imaging in rats,” British Journal of Pharmacology, vol. 162, no. 3, pp. 659–672, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. Z. Liu, L. wyffels, C. Barber, M. M. Hui, and J. M. Woolfenden, “A 99mTc-labeled dual-domain cytokine ligand for imaging of inflammation,” Nuclear Medicine and Biology, vol. 38, no. 6, pp. 795–805, 2011. View at Publisher · View at Google Scholar · View at Scopus
  115. X. Geng, R. Zhang, G. Yang, W. Jiang, and C. Xu, “Interleukin-2 and autoimmune disease occurrence and therapy,” European Review for Medical and Pharmacological Sciences, vol. 16, no. 11, pp. 1462–1467, 2012. View at Google Scholar · View at Scopus
  116. T. R. Malek and I. Castro, “Interleukin-2 receptor signalling: at the interface between tolerance and immunity,” Immunity, vol. 33, no. 2, pp. 153–165, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. U. Karczmarczyk, P. Garnuszek, M. Maurin et al., “Investigation of 99mTc-labelling of recombinant human interleukin-2 via hydrazinonicotinamide,” Nuclear Medicine and Biology, vol. 37, no. 7, pp. 795–803, 2010. View at Publisher · View at Google Scholar · View at Scopus
  118. C. D'Alessandria, V. di Gialleonardo, M. Chianelli et al., “Synthesis and optimization of the labeling procedure of 99mTc-Hynic-interleukin-2 for in vivo imaging of activated T lymphocytes,” Molecular Imaging and Biology, vol. 12, no. 5, pp. 539–546, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. V. di Gialleonardo, A. Signore, A. W. J. M. Glaudemans, R. A. J. O. Dierckx, and E. F. J. de Vries, “N-(4-18F-fluorobenzoyl)interleukin-2 for PET of human-activated T lymphocytes,” Journal of Nuclear Medicine, vol. 53, no. 5, pp. 679–686, 2012. View at Publisher · View at Google Scholar · View at Scopus
  120. M. Opalinska, T. Stompor, D. Pach et al., “Imaging of inflamed carotid artery atherosclerotic plaques with the use of 99mTc-HYNIC-IL-2 scintigraphy in end-stage renal disease patients,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 4, pp. 673–682, 2012. View at Publisher · View at Google Scholar · View at Scopus
  121. A. Signore, M. Chianelli, A. Annovazzi et al., “123I-Interleukin-2 scintigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn's disease,” Journal of Nuclear Medicine, vol. 41, no. 2, pp. 242–249, 2000. View at Google Scholar · View at Scopus
  122. L. M. Campbell, P. J. Maxwell, and D. J. J. Waugh, “Rationale and means to target pro-inflammatory interleukin-8 (CXCL8) signaling in cancer,” Pharmaceuticals, vol. 6, no. 8, pp. 929–959, 2013. View at Publisher · View at Google Scholar · View at Scopus
  123. B. Moser, “Chemokines: role in immune cell traffic,” European Cytokine Network, vol. 14, no. 4, pp. 204–210, 2003. View at Google Scholar · View at Scopus
  124. H. J. J. M. Rennen, O. C. Boernan, W. J. G. Oyen, J. W. M. Van der Meer, and F. H. M. Corstens, “Specific and rapid scintigraphic detection of infection with 99mTc-labeled interleukin-8,” Journal of Nuclear Medicine, vol. 42, no. 1, pp. 117–123, 2001. View at Google Scholar · View at Scopus
  125. S. Gratz, H. J. J. M. Rennen, O. C. Boerman, W. J. G. Oyen, and F. H. M. Corstens, “Rapid imaging of experimental colitis with 99mTc-interleukin-8 in rabbits,” Journal of Nuclear Medicine, vol. 42, no. 6, pp. 917–923, 2001. View at Google Scholar · View at Scopus
  126. S. Gratz, H. J. J. M. Rennen, O. C. Boerman, W. J. G. Oyen, P. Burma, and F. H. M. Corstens, “99mTc-interleukin-8 for imaging acute osteomyelitis,” Journal of Nuclear Medicine, vol. 42, no. 8, pp. 1257–1264, 2001. View at Google Scholar · View at Scopus
  127. H. J. J. M. Rennen, C. P. Bleeker-Rovers, J. E. M. Van Erd et al., “99mTc-labeled interleukin-8 for scintigraphic detection of pulmonary infections,” Chest, vol. 126, no. 6, pp. 1954–1961, 2004. View at Publisher · View at Google Scholar · View at Scopus
  128. C. P. Bleeker-Rovers, H. J. J. M. Rennen, O. C. Boerman et al., “99mTc-labeled interleukin 8 for the scintigraphic detection of infection and inflammation: first clinical evaluation,” Journal of Nuclear Medicine, vol. 48, no. 3, pp. 337–343, 2007. View at Google Scholar · View at Scopus
  129. H. J. J. M. Rennen, C. Frielink, E. Brandt et al., “Relationship between neutrophil-binding affinity and suitability for infection imaging: comparison of 99mTc-labeled NAP-2 (CXCL-7) and 3 C-terminally truncated isoforms,” Journal of Nuclear Medicine, vol. 45, no. 7, pp. 1217–1223, 2004. View at Google Scholar · View at Scopus
  130. A. M. Barrie III and S. E. Plevy, “The interleukin-12 family of cytokines: therapeutic targets for inflammatory disease mediation,” Clinical and Applied Immunology Reviews, vol. 5, no. 4, pp. 225–240, 2005. View at Publisher · View at Google Scholar · View at Scopus
  131. T. Hamza, J. B. Barnett, and B. Li, “Interleukin 12 a key immunoregulatory cytokine in infection applications,” International Journal of Molecular Sciences, vol. 11, no. 3, pp. 789–806, 2010. View at Publisher · View at Google Scholar · View at Scopus
  132. A. Annovazzi, C. D'Alessandria, E. Bonanno et al., “Synthesis of 99mTc-HYNIC-interleukin-12, a new specific radiopharmaceutical for imaging T lymphocytes,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 4, pp. 474–482, 2006. View at Publisher · View at Google Scholar · View at Scopus
  133. P. N. Monk, A.-M. Scola, P. Madala, and D. P. Fairlie, “Function, structure and therapeutic potential of complement C5a receptors,” British Journal of Pharmacology, vol. 152, no. 4, pp. 429–448, 2007. View at Publisher · View at Google Scholar · View at Scopus
  134. J. E. M. van Eerd, O. C. Boerman, F. H. M. Corstens, and W. J. G. Oyen, “Radiolabeled chemotactic cytokines: new agents for scintigraphic imaging of infection and inflammation,” Quarterly Journal of Nuclear Medicine, vol. 47, no. 4, pp. 246–255, 2003. View at Google Scholar · View at Scopus
  135. R. Huey and T. E. Hugli, “Characterization of a C5a receptor on human polymorphonuclear leukocytes (PMN),” Journal of Immunology, vol. 135, no. 3, pp. 2063–2068, 1985. View at Google Scholar · View at Scopus
  136. H. J. Rennen, W. J. Oyen, S. A. Cain, P. N. Monk, F. H. Corstens, and O. C. Boerman, “Tc-99m-labeled C5a and C5a des Arg74 for infection imaging,” Nuclear Medicine and Biology, vol. 30, no. 3, pp. 267–272, 2003. View at Publisher · View at Google Scholar · View at Scopus
  137. M. M. Welling, P. H. Nibbering, A. Paulusma-Annema, P. S. Hiemstra, E. K. J. Pauwels, and W. Calame, “Imaging of bacterial infections with 99mTc-labeled human neutrophil peptide-1,” Journal of Nuclear Medicine, vol. 40, no. 12, pp. 2073–2080, 1999. View at Google Scholar · View at Scopus
  138. M. M. Welling, A. Paulusma-Annema, H. S. Balter, E. K. J. Pauwels, and P. H. Nibbering, “Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations,” European Journal of Nuclear Medicine, vol. 27, no. 3, pp. 292–301, 2000. View at Publisher · View at Google Scholar · View at Scopus
  139. M. M. Welling, A. Lupetti, H. S. Balter et al., “99mTc-labeled antimicrobial peptides for detection of bacterial and Candida albicans infections,” Journal of Nuclear Medicine, vol. 42, no. 5, pp. 788–794, 2001. View at Google Scholar · View at Scopus
  140. G. Ferro-Flores, F. D. M. Ramírez, L. Meléndez-Alafort, C. A. D. Murphy, and M. Pedraza-López, “Molecular recognition and stability of 99mTc-UBI 29-41 based on experimental and semiempirical results,” Applied Radiation and Isotopes, vol. 61, no. 6, pp. 1261–1268, 2004. View at Publisher · View at Google Scholar · View at Scopus
  141. M. M. Welling, A. Korsak, B. Gorska et al., “Kit with technetium-99m labelled antimicrobial peptide UBI 29–41 for specific infection detection,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 48, no. 9, pp. 683–691, 2005. View at Publisher · View at Google Scholar · View at Scopus
  142. M. S. Akhtar, A. Qaisar, J. Irfanullah et al., “Antimicrobial peptide 99mTc-Ubiquicidin 29-41 as human infection-imaging agent: Clinical trial,” Journal of Nuclear Medicine, vol. 46, no. 4, pp. 567–573, 2005. View at Google Scholar · View at Scopus
  143. J. J. M. Huub, O. C. Rennen, W. J. G. Boerman, W. J. Oyen, and F. H. M. Corstens, “Scintigraphic imaging of inflammatory processes,” Current Medicinal Chemistry-Anti-Inflammatory & Anti-Allergy Agents, vol. 1, pp. 63–75, 2002. View at Google Scholar
  144. J. W. Babich, R. G. Tompkins, W. Graham, S. A. Barrow, and A. J. Fischman, “Localization of radiolabeled chemotactic peptide at focal sites of Escherichia coli infection in rabbits: evidence for a receptor-specific mechanism,” Journal of Nuclear Medicine, vol. 38, no. 8, pp. 1316–1322, 1997. View at Google Scholar · View at Scopus
  145. A. J. Fischman, D. Rauh, H. Solomon et al., “In vivo bioactivity and biodistribution of chemotactic peptide analogs in nonhuman primates,” Journal of Nuclear Medicine, vol. 34, no. 12, pp. 2130–2134, 1993. View at Google Scholar · View at Scopus
  146. A. Lupetti, E. K. J. Pauwels, P. H. Nibbering, and M. M. Welling, “99mTc-Antimicrobial peptides: Promising candidates for infection imaging,” Quarterly Journal of Nuclear Medicine, vol. 47, no. 4, pp. 238–245, 2003. View at Google Scholar · View at Scopus
  147. http://www.imgt.org/IMGTrepertoire/GenesClinical/monoclonalantibodies/.